European Medicines Agency recommends approval of Hexyon/Hexacima 6-in-1 pediatric vaccine
22 February 2013 | By Sanofi
The EMA recommended market approval for Sanofi Pasteur’s 6-in-1 pediatric vaccine...
List view / Grid view
News
FDA approves Roche’s Kadcyla (trastuzumab emtansine)
22 February 2013 | By Roche
New personalised medicine helped people in Phase III study live longer, compared to standard treatment...
Tecan microarray solutions transform functional proteomics workflows at ASU
21 February 2013 | By kdm communications
“We have adopted a unique approach to functional proteomics..."
ARIAD announces appointment of European General Manager and other key members of leadership team
21 February 2013 | By Biosector 2
ARIAD announced the appointment of Jonathan E. Dickinson...
New findings from two studies support substantial benefit of Pradaxa® for prevention of recurrent deep vein thrombosis and pulmonary embolism
21 February 2013 | By Boehringer Ingelheim
Findings from two trials...
Abbott to collaborate with Janssen and Pharmacyclics
21 February 2013 | By Abbott
Abbott will collaborate with Janssen Biotech and Pharmacyclics to explore the benefits of Abbott's proprietary FISH technology...
Announcement of application for approval in Japan of DPT-IPV vaccine
20 February 2013 | By Daiichi Sankyo
DPT-IPV vaccine for prevention of Diphtheria, Pertussis, Tetanus, and acute Poliomyelitis...
Phase 3 data shows bendamustine plus rituximab doubles progression-free survival in patients with iNHL and MCL compared with CHOP-R
Results from the StiL NHL-1 study...
Merck and Samsung Bioepis enter biosimilars development and commercialization agreement
20 February 2013 | By Merck
Merck and Samsung Bioepis Co., Ltd., entered into an agreement...
Gilead and Teva reach settlement agreement in Viread ® patent litigation
19 February 2013 | By Gilead Sciences
Gilead and Teva Pharmaceuticals have reached an agreement in principle to settle the ongoing patent litigation...
Shire’s VPRIV® wins first ever “Novel Treatment Award”
19 February 2013 | By Edelman on behalf of Shire
"Shire has demonstrated its commitment to developing new therapies for the treatment of rare genetic diseases..."
Gilead’s sofosbuvir for hepatitis C meets primary endpoint in fourth pivotal Phase 3 study
19 February 2013 | By Gilead Sciences
Topline results from the Phase 3 FUSION study...
Sanofi New Drug Application for Lixisenatide accepted for review by FDA
19 February 2013 | By Sanofi
Sanofi announced that the U.S. FDA has accepted for review a New Drug Application for lixisenatide...
GSK and Theravance announce FDA acceptance of NDA submission in the US for ANORO ELLIPTATM for COPD
19 February 2013 | By GlaxoSmithKline
The NDA for the investigational once-daily LAMA/LABA combination medicine, UMEC/VI has been accepted...
Novartis drug Zortress® is first in over a decade approved by FDA to prevent organ rejection in adult liver transplant patients
15 February 2013 | By Novartis
The FDA has approved Zortress®...
